The American Academy of Neurology (AAN) Annual Meeting brings together an international attendance of the neurology committee to promote the highest quality patient-centered neurologic care, convey the latest advances, and enhance career satisfaction.
Understanding the Impact of Data Analysis on Preventive Migraine Treatment: Jessica Ailani, MD
May 7th 2024The director of the MedStar Georgetown Headache Center discussed the importance of maintaining hope and providing understanding of patients' frustrations in their treatment journey for migraine. [WATCH TIME: 5 minutes]
Understanding the Therapeutic Potential of Nipocalimab: Katie Abouzahr, MD
May 6th 2024The vice president, Autoantibody Portfolio and Maternal Fetal Immunology Disease Area Leader, Johnson & Johnson, provided perspective on the unique molecular structure of nipocalimab seen across nonclinical and clinical studies. [WATCH TIME: 3 minutes]
A Call to Action to Address Disparities in Multiple Sclerosis Care: Jaime Imitola, MD
May 6th 2024The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]
Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD
May 3rd 2024The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]
Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods
May 2nd 2024Tanisha Hill-Jarrett, PhD, an assistant professor of neurology at the University of California, San Francisco Memory and Aging Center, discussed the change needed to improve cognitive decline rates in Black women in disadvantaged neighborhoods.
Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD
May 2nd 2024The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]
Latest Findings on AXS-05 Treatment for Agitation in Alzheimer Disease: Anton P. Porsteinsson, MD
May 1st 2024The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 8 minutes]
Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments
April 29th 2024In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.
Promise of Neuroprotection in Neurodegenerative Diseases Through HGF Compounds: Kevin Church, PhD
April 24th 2024The chief scientific officer at Athira talked about the potential of hepatocyte growth factor compounds in promoting neurotrophic signaling and providing broad neuroprotection across neurodegenerative diseases. [WATCH TIME: 6 minutes]
Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC: Merit Cudkowicz, MD, MSc
April 24th 2024The chair of neurology at Massachusetts General Hospital talked about results from the phase 2b PARADIGM trial assessing PrimeC, an ALS combination agent that consists of ciprofloxacin and celecoxib. [WATCH TIME: 4 minutes]
Understanding the Clinical Utility of Low-Contrast Letter Acuity and RAN Tasks in Alzheimer Disease
April 23rd 2024Lauren Seidman, a second-year medical student at NYU Langone’s Grossman School of Medicine, provided perspective on a poster at AAN 2024 highlighting the use of binocular visual function testing in Alzheimer disease.
Consistent Efficacy of Eptinezumab as Migraine Prevention Treatment: Jessica Ailani, MD
April 22nd 2024The director of the MedStar Georgetown Headache Center talked about an intravenous migraine treatment that could offer long-term relief for most patients who respond well to the initial dose. [WATCH TIME: 5 minutes]
Takotsubo Syndrome and the Brain-Heart Connection: Frederic Schaper, MD, PhD
April 19th 2024The instructor in neurology at Brigham and Women's Hospital talked about research exploring takotsubo syndrome, a heart condition often triggered by emotional or physical stressors, and its relationship with brain lesions. [WATCH TIME: 5 minutes]
Impact of Antiepileptic Medications and Sex Hormones on Maternal and Child Outcomes in Epilepsy
April 18th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
A Promising New Approach To Reduce Repeat Surgeries for Subdural Hematomas: Jason M. Davies, MD, PhD
April 18th 2024The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo talked about the potential of embolizing the middle meningeal artery in patients with subdural hematomas. [WATCH TIME: 4 minutes]